Trebananib (AMG 386) in Combination With Docetaxel for Advanced Urothelial Carcinoma

Summary

This study plans to learn more about the combination of AMG 386 and docetaxel for the treatment of advanced urothelial cancer. Subjects are being asked to be in this research study because they have advanced urothelial cancer which has progressed after treatment with a platinum-based therapy. The hypothesis is that AMG 386 will increase the historical response rate of docetaxel as a single agent.

Timeline

Start

2014-02

Primary completion

2014-04

Completion

2014-04

Drugs

Indications